Biocon Biologics in Malaysia
Biocon Biologics is a unique, fully integrated, global biosimilars company with world-class ‘lab to market’ capabilities across development, manufacturing, and marketing.
It is present in over 120 countries, including over 80 Emerging Market countries, where it is providing sustainable solutions for a healthier world through its cost-effective, high-quality biosimilars.
To serve the global demand for insulins, Biocon Biologics has created a Center of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities for manufacturing its robust portfolio of human insulin and insulin analogs. The integrated manufacturing and R&D facility is the largest in Asia, and it manufactures a broad portfolio of regular, basal, and rapid-acting insulins. Commercial operations at the facility commenced in 2016 when Biocon Biologics’ recombinant human insulin became the first locally manufactured biosimilar product approved for sale in Malaysia.
Expanding Access to Lifesaving Therapies in APAC
Biocon Biologics has developed a differentiated portfolio of biosimilars spanning insulins, monoclonal antibodies and conjugated recombinant proteins by leveraging its deep experience in biotechnology.
In the Asia-Pacific (APAC) region, Biocon Biologics is making a significant impact on patients’ lives by expanding access to lifesaving treatments and life-improving therapies to treat diseases like diabetes, cancer, and autoimmune conditions through its 7 commercialized biosimilars.
It addresses the needs of patients in the APAC region through its state-of-the-art manufacturing infrastructure, which includes facilities for producing monoclonal antibodies in Bengaluru, India, and insulins in Johor, Malaysia.
Focused on Making a Meaningful Difference in Malaysia
In Malaysia, the company is focused on broadening access to biosimilars for patients and improving healthcare outcomes through its three commercialized biosimilars for treating diabetes — Insugen (rh-Insulin), Basalog One (Insulin Glargine) and Kirsty (Insulin Aspart) — and two oncology biosimilars — Zuhera (Trastuzumab) and Krabeva (Bevacizumab). In Malaysia, all our products are commercialized by our partner Duopharma.
Headquartered in Bengaluru, global biosimilars leader Biocon Biologics has a longstanding presence in the industry, having invested over $1 billion in R&D and global-scale manufacturing over the past two decades. The integration of the global biosimilars business acquired from its long-term partner has further strengthened Biocon Biologics’ commercial presence in Malaysia. As a trusted and reliable company, Biocon Biologics is poised to consolidate its leadership in biosimilars in Malaysia, making a meaningful impact on patients’ lives.
Commercialized Products
| Sl. No | Brand Name | Molecule Name | THERAPY AREA |
| 1 | Insugen | rh-Insulin | Diabetes |
| 2 | Basalog One | Insulin Glargine | Diabetes |
| 3 | Kirsty | Insulin Aspart | Diabetes |
| 4 | Zuhera | Trastuzumab | Cancer |
| 5 | Krabeva | Bevacizumab | Cancer |
Meet the Leaders
Delivering Highest-Quality Products Globally
80+
03
90+
Our Vision & Values
To be a global leader
in biologics, delivering affordable access to innovative and inclusive healthcare solutions, transforming
patients’ lives.
- Value creation through innovation and differentiation
- Collaboration, teamwork and mutual respect
- Performance-driven work culture
- Quality through compliance and best practices
- Integrity and ethical behaviour
The Biocon Advantage
*19th Annual Report of BioPlan Associates
